Srdjan Nedeljkovic, MD
Anesthesiology · Brighton, MANPI 1457347015
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,420 of the $17,562 with a category attached, or 99.2%. Every reported general payment came from a single manufacturer, Pacira Pharmaceuticals Incorporated. Among anesthesiology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $1350.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Pharmaceuticals Incorporated$18K
Across 9 payments — averaging $76,010 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pacira Pharmaceuticals Incorporated$683K
- Dova Pharmaceuticals$1K
What the payments were for
- Consulting fees$17,42099%
- Travel & lodging$1421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Pharmaceuticals Incorporated | 13 | $17,562 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EXPAREL$17,420
How this compares
$17,562 in reported general payments places this provider in the 95th percentile of 1,585 anesthesiology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NeurontinGabapentin | 13 | $5,020 |
| Lidocaine | 30 | $2,157 |
| Gabapentin | 112 | $1,760 |
| Baclofen | 43 | $699 |
| Duloxetine Hcl | 61 | $656 |
| Pregabalin | 16 | $409 |
| Tizanidine Hcl | 45 | $398 |
| Methocarbamol | 19 | $251 |
| Cyclobenzaprine Hcl | 16 | $226 |
| Meloxicam | 38 | $125 |
Paid to pharmacies, not to this prescriber.
Other anesthesiology in Brighton
- James StreisandCambridge$380K
- Douglas ShookBoston$267K
- Paula BokeschLexington$244K
- Robert YongBoston$231K
- Michael DambraBoston$194K
- Jasmine PatelWorcester$180K
- Robert TruogBoston$172K
- Mary Ellen McCannBoston$140K
- Stanton ShernanBoston$136K
- Edgar RossBoston$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.